Delving into the Latest Updates on Hangzhou Aojin Biomedical Technology Co Ltd with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	1
BTK(Tyrosine-protein kinase BTK)	1

主要目的： 1.评价CX1440单次以及多次给药在健康受试者中的安全性与耐受性； 2.评估食物对CX1440药代动力学特征的影响。次要目的 1.评价CX1440单次和多次给药的药代动力学特征； 2.测量药效学（PD）参数，包括BTK靶酶的药物占有率。

[Translation]

Primary objectives: 1. Evaluate the safety and tolerability of single and multiple doses of CX1440 in healthy subjects; 2. Evaluate the effect of food on the pharmacokinetic characteristics of CX1440. Secondary objectives 1. Evaluate the pharmacokinetic characteristics of single and multiple doses of CX1440; 2. Measure pharmacodynamic (PD) parameters, including drug occupancy of the BTK target enzyme.

Start Date18 Nov 2021

Sponsor / Collaborator

Hangzhou Aojin Biomedical Technology Co Ltd

[+1]

CTR20201693 / RecruitingPhase 1

CX1440胶囊在复发/难治B淋巴细胞恶性肿瘤患者中的耐受性、安全性、药代动力学、药效学和有效性的剂量递增试验、剂量探索和剂量扩展试验。

[Translation] Dose escalation, dose exploratory and dose expansion trials of CX1440 capsules to evaluate the tolerability, safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory B-lymphocytic malignancies.

主要目的观察口服不同剂量的CX1440胶囊在复发/难治B淋巴细胞恶性肿瘤患者中的安全性和耐受性，确定可能出现的最大耐受剂量（MTD）和剂量限制性毒性（DLT）。次要目的考察单次和多次连续给药口服CX1440胶囊在人体内的药代动力学（PK）参数。测量药效学（PD）参数，包括BTK靶酶的药物占有率。初步评估CX1440胶囊的临床抗肿瘤疗效。

[Translation]

Primary objective To observe the safety and tolerability of oral CX1440 capsules at different doses in patients with relapsed/refractory B-lymphocyte malignancies and determine the possible maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary objective To investigate the pharmacokinetic (PK) parameters of single and multiple continuous oral administration of CX1440 capsules in humans. To measure pharmacodynamic (PD) parameters, including drug occupancy of BTK target enzyme. To preliminarily evaluate the clinical anti-tumor efficacy of CX1440 capsules.

Start Date16 Sep 2020

Sponsor / Collaborator

Hangzhou Aojin Biomedical Technology Co Ltd

[+1]

CTR20201948 / CompletedPhase 1

评价类风湿关节炎患者中OB756片与甲氨蝶呤片药物相互作用的开放、自身对照研究

[Translation] An open, self-controlled study to evaluate the drug interaction between OB756 tablets and methotrexate tablets in patients with rheumatoid arthritis

主要目的：评价类风湿关节炎患者口服OB756和MTX的药物代谢动力学（PK）相互作用。次要目的：评价类风湿关节炎患者口服OB756和MTX的安全性。

[Translation]

Primary objective: To evaluate the pharmacokinetic (PK) interaction between oral OB756 and MTX in patients with rheumatoid arthritis. Secondary objective: To evaluate the safety of oral OB756 and MTX in patients with rheumatoid arthritis.

Start Date14 Sep 2020

Sponsor / Collaborator

Hangzhou Guangliang Biomedical Co., Ltd.

[+1]

100 Clinical Results associated with Hangzhou Aojin Biomedical Technology Co Ltd

Login to view more data

0 Patents (Medical) associated with Hangzhou Aojin Biomedical Technology Co Ltd

Login to view more data

100 Deals associated with Hangzhou Aojin Biomedical Technology Co Ltd

Login to view more data

100 Translational Medicine associated with Hangzhou Aojin Biomedical Technology Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CX1440 ( BTK )	B-Cell Malignant Neoplasm More	Phase 1
CX510 ( HER2 )	Non-Small Cell Lung Cancer More	Phase 1
Bewintinib ( JAK )	Rheumatoid Arthritis More	Pending